Willow vs Maximus: Oral GLP-1 with tracking vs low-cost semaglutide

Quick verdict: Willow emphasizes a structured oral GLP-1 program with progress tracking and follow-up consultations, while Maximus offers a lower flat-rate compounded semaglutide program via telemedicine for $132.99 per month.

See Willow’s oral GLP-1 program and tracking

Willow vs Maximus: core differences at a glance

This comparison focuses on the most distinctive differences: pricing model, care and support structure, medication sourcing and regulatory notes, telehealth and clinician review, and availability details. Each point below compares Willow and Maximus directly using the captured source facts.

1. Price and pricing model

Maximus positions itself as a low-cost, direct-pay option with a clear starting point: “$132.99 per Month” for compounded semaglutide and several references to “starting at $79.99” or similar starter-pack pricing on landing content. Willow’s captured evidence lists a starting price of 299 and notes “higher monthly entry pricing for some plans.” Use Maximus if predictable low flat-rate monthly cost is a primary concern; use Willow if you prioritize the program model over the lowest price.

2. Care model and ongoing support

Willow frames its program as a structured weight management journey: “oral GLP-1 with progress tracking. Follow-up included,” emphasizing progress tracking tools, follow-up consultations, and a licensed telehealth team. Maximus emphasizes convenience and simplicity: telemedicine access, prescriptions approved by licensed doctors, and medication filled through trusted U.S. pharmacies, with a straightforward direct-pay model. If behavioral scaffolding and structured follow-up are priorities, Willow emphasizes that model. If you want a no-frills telemedicine prescription and low price, Maximus highlights that approach.

3. Medication type, sourcing, and regulatory notes

Maximus offers compounded semaglutide filled through U.S. pharmacies; its materials state the medication is compounded and not an FDA-approved finished product, while also noting semaglutide is an active ingredient used in FDA-approved GLP-1s. Willow’s captured evidence warns that when compounded medications are offered they are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Both sources include regulatory qualifiers: compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

4. Telehealth and clinician review

Both providers operate via telemedicine and involve licensed clinicians. Willow is described as “telehealth-first” with a licensed telehealth team and follow-up consultations; treatment is available only when a licensed clinician determines it is medically appropriate. Maximus states prescriptions are approved by licensed doctors and no in-person clinic visits are required. The difference is Willow pairs telehealth with ongoing tracking and follow-up, while Maximus emphasizes quick telemedicine access and prescription fulfillment.

5. Availability and program details

Maximus notes broad availability: the Weight Loss Protocol is available in all 50 states except Mississippi, and it offers free expedited shipping and refund of medication costs if not approved. Willow’s captured landing-page evidence was not readable for verification; the site evidence included a browser error and did not capture expanded FAQ or shipping and membership details. Where specific state or shipping claims are important, Maximus provides clearer captured details; Willow’s captured page lacked readable evidence on availability and shipping.

Comparison table: Willow vs Maximus

How outcomes and claims are presented

Maximus’s materials reference published semaglutide study results and note semaglutide’s demonstrated weight loss in trials and related cardiovascular findings; those are presented in Maximus content as supporting context. Willow frames its offering as converting GLP-1 efficacy into sustainable outcomes through structured follow-up, positioning the program around behavioral support rather than direct outcome claims. Neither source captured a medical guarantee; both include regulatory qualifiers about compounded medication status where applicable.

View Maximus pricing and telemedicine details

Practical recommendation and closing guidance

Choose Willow if you want a telehealth-first oral GLP-1 program built around progress tracking tools and ongoing follow-up consultations and accept a higher monthly entry price. Choose Maximus if your priority is a lower flat-rate compounded semaglutide program delivered via telemedicine with prescriptions filled through trusted U.S. pharmacies and clear captured pricing at $132.99 per month.

Explore Willow’s tracked program and follow-up

Check Maximus availability and shipping

Sign up for Willow’s clinician-reviewed program

Primary keyword: Willow vs Maximus